Simplicity Wealth LLC Has $640,000 Holdings in Novartis AG $NVS

Simplicity Wealth LLC lessened its holdings in shares of Novartis AG (NYSE:NVS) by 41.9% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 4,992 shares of the company’s stock after selling 3,594 shares during the period. Simplicity Wealth LLC’s holdings in Novartis were worth $640,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of the stock. Blue Trust Inc. raised its position in shares of Novartis by 1.7% during the third quarter. Blue Trust Inc. now owns 4,763 shares of the company’s stock worth $611,000 after acquiring an additional 78 shares during the last quarter. WealthPlan Investment Management LLC increased its holdings in shares of Novartis by 0.9% in the third quarter. WealthPlan Investment Management LLC now owns 9,394 shares of the company’s stock worth $1,205,000 after acquiring an additional 80 shares in the last quarter. Capital Advisors Inc. OK raised its holdings in Novartis by 4.3% during the 3rd quarter. Capital Advisors Inc. OK now owns 2,027 shares of the company’s stock worth $260,000 after buying an additional 83 shares during the period. Glenview Trust co lifted its position in Novartis by 2.3% in the 2nd quarter. Glenview Trust co now owns 3,800 shares of the company’s stock valued at $460,000 after acquiring an additional 84 shares in the last quarter. Finally, Deroy & Devereaux Private Investment Counsel Inc. boosted its position in shares of Novartis by 4.4% during the second quarter. Deroy & Devereaux Private Investment Counsel Inc. now owns 2,062 shares of the company’s stock worth $250,000 after buying an additional 87 shares during the period. Institutional investors own 13.12% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. Barclays raised Novartis from an “underweight” rating to an “equal weight” rating in a research report on Tuesday, January 6th. HC Wainwright cut Novartis to a “neutral” rating in a report on Monday, October 27th. JPMorgan Chase & Co. raised shares of Novartis from a “neutral” rating to an “overweight” rating in a report on Monday, December 8th. Cfra Research upgraded shares of Novartis to a “hold” rating in a research report on Wednesday, October 29th. Finally, Wall Street Zen upgraded shares of Novartis from a “hold” rating to a “buy” rating in a research report on Saturday, January 17th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, seven have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, Novartis presently has an average rating of “Hold” and a consensus target price of $119.75.

Novartis Price Performance

NVS stock opened at $147.27 on Friday. The company has a debt-to-equity ratio of 0.50, a current ratio of 0.88 and a quick ratio of 0.68. Novartis AG has a 1 year low of $97.71 and a 1 year high of $148.10. The company’s 50-day moving average is $136.23 and its 200-day moving average is $128.65. The stock has a market capitalization of $311.09 billion, a PE ratio of 20.12, a price-to-earnings-growth ratio of 1.92 and a beta of 0.51.

Novartis (NYSE:NVS) last issued its earnings results on Tuesday, October 28th. The company reported $2.25 earnings per share for the quarter, missing analysts’ consensus estimates of $2.26 by ($0.01). Novartis had a return on equity of 41.21% and a net margin of 26.49%.The firm had revenue of $14.36 billion for the quarter, compared to analyst estimates of $13.70 billion. During the same period in the previous year, the company earned $2.06 earnings per share. Novartis’s revenue for the quarter was up 8.5% compared to the same quarter last year. Equities research analysts expect that Novartis AG will post 8.45 EPS for the current fiscal year.

Novartis Company Profile

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.